Lei Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lei Zhou has a total of 219 co-authors. Here are the top co-authors by number of shared publications:
Chengyun Ning
School of Materials Science and Engineering National Engineering Research Center for Tissue Restoration and Reconstruction South China University of Technology Guangzhou China
22 shared publications- Guoxin Tan
School of Chemical Engineering and Light Industry Guangdong University of Technology Guangzhou 510006 P. R. China
17 shared publications Lei Fan
Department of Orthopedic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China
13 shared publicationsRumin Fu
Key Laboratory of Crop Physiology, Ecology and Genetic Breeding, Ministry of Education, Key Laboratory of Chemical Utilization of Plant Resources of Nanchang College of Chemistry and Materials
10 shared publicationsTianhua Xiao
School of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou, 510006, China
9 shared publicationsXinchang Kang
School of Chemical Engineering and Light Industry Guangdong University of Technology Guangzhou 510006 P. R. China
8 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Wiley in Advanced Science
A Dual‐Functional Nanoplatform Targeting the dsDNA–cGAS Axis to Mitigate Disc Degeneration and Aberrant Innervation
Pathological sensory nerve ingrowth into degenerated intervertebral discs contributes to discogenic pain, yet strategies that concurrently mitigate disc degeneration and pathological innervation remain limited. Here, we found that senescent nucleus pulposus (NP) cells accumulated and released double‐stranded DNA (dsDNA), which reinforced NP cell senescence and matrix catabolism. The accumulated dsDNA also activated cGAS–STING signaling, increased Netrin‐1 expression, and promoted neuronal migration and neurite outgrowth. Guided by these findings, we developed RU@PEI‐ZIF, a dual‐functional nanoplatform combining PEI‐mediated dsDNA scavenging with ZIF‐8‐mediated delivery of the cGAS inhibitor RU.521. RU@PEI‐ZIF displayed dsDNA‐binding capacity, cytocompatibility, and pH‐responsive RU.521 release. In senescent NP cells, RU@PEI‐ZIF reduced extracellular and cytosolic dsDNA, attenuated cGAS–STING‐associated inflammatory and neurotrophic signaling, and reduced NP cell‐mediated neuronal migration and neurite outgrowth. In an animal model of disc degeneration, intradiscal RU@PEI‐ZIF reduced disc degeneration, NP cell senescence, pathological sensory innervation, and pain hypersensitivity. These findings support RU@PEI‐ZIF as a dual‐action nanotherapeutic strategy targeting both disc degeneration and pathological innervation.
- 12 October 2026
- Published by Wiley in Advanced Science
Open AccessA Dual‐Functional Nanoplatform Targeting the dsDNA–cGAS Axis to Mitigate Disc Degeneration and Aberrant Innervation
Pathological sensory nerve ingrowth into degenerated intervertebral discs contributes to discogenic pain, yet strategies that concurrently mitigate disc degeneration and pathological innervation remain limited. Here, we found that senescent nucleus pulposus (NP) cells accumulated and released double‐stranded DNA (dsDNA), which reinforced NP cell senescence and matrix catabolism. The accumulated dsDNA also activated cGAS–STING signaling, increased Netrin‐1 expression, and promoted neuronal migration and neurite outgrowth. Guided by these findings, we developed RU@PEI‐ZIF, a dual‐functional nanoplatform combining PEI‐mediated dsDNA scavenging with ZIF‐8‐mediated delivery of the cGAS inhibitor RU.521. RU@PEI‐ZIF displayed dsDNA‐binding capacity, cytocompatibility, and pH‐responsive RU.521 release. In senescent NP cells, RU@PEI‐ZIF reduced extracellular and cytosolic dsDNA, attenuated cGAS–STING‐associated inflammatory and neurotrophic signaling, and reduced NP cell‐mediated neuronal migration and neurite outgrowth. In an animal model of disc degeneration, intradiscal RU@PEI‐ZIF reduced disc degeneration, NP cell senescence, pathological sensory innervation, and pain hypersensitivity. These findings support RU@PEI‐ZIF as a dual‐action nanotherapeutic strategy targeting both disc degeneration and pathological innervation.
- Open Access
- 31 August 2026
- Published by Wiley in Advanced Science
- p. e77569
An Injectable Metal‐Drug Supramolecular Condensate Enables Radiosensitization and Systemic Antitumor Immunity for Post‐Surgical Osteosarcoma Therapy
Radiotherapy (RT) is widely used as an adjuvant treatment after surgical resection for osteosarcoma, but its efficacy is often limited by insufficient radiosensitization and an immunosuppressive tumor microenvironment that restricts systemic antitumor immunity and promotes recurrence and metastasis. Here we report an injectable metal‐drug supramolecular condensate formed from hafnium ions and alendronate (Hf‐ALN) and loaded with the COX‐2 inhibitor celecoxib (CXB) for synergistic radioimmunotherapy of postoperative osteosarcoma. The condensate forms through coordination‐driven liquid‐liquid phase separation between Hf 4+ ions and alendronate, enabling local retention within postoperative bone defects and sustained therapeutic release. Upon X‐ray irradiation, the Hf component amplifies radiation energy deposition and reactive oxygen species generation, thereby enhancing radiation‐induced DNA damage and immunogenic cell death. Meanwhile, the acidic tumor microenvironment triggers responsive release of CXB and ALN; CXB inhibits the COX‐2/PGE 2 immunosuppressive pathway, while ALN promotes macrophage repolarization toward the M1 phenotype, collectively remodeling the tumor immune microenvironment. This strategy enhances dendritic cell maturation, activates cytotoxic CD8 + T cells, and reduces regulatory T‐cell infiltration. In orthotopic osteosarcoma models, CXB@Hf‐ALN combined with RT suppresses tumor recurrence, preserves bone integrity, inhibits pulmonary metastasis, and prolongs survival with minimal systemic toxicity, offering a promising strategy to improve postsurgical RT outcomes in osteosarcoma.
- 31 August 2026
- Published by Wiley in Advanced Science
- p. e77569
Open AccessAn Injectable Metal‐Drug Supramolecular Condensate Enables Radiosensitization and Systemic Antitumor Immunity for Post‐Surgical Osteosarcoma Therapy
Radiotherapy (RT) is widely used as an adjuvant treatment after surgical resection for osteosarcoma, but its efficacy is often limited by insufficient radiosensitization and an immunosuppressive tumor microenvironment that restricts systemic antitumor immunity and promotes recurrence and metastasis. Here we report an injectable metal‐drug supramolecular condensate formed from hafnium ions and alendronate (Hf‐ALN) and loaded with the COX‐2 inhibitor celecoxib (CXB) for synergistic radioimmunotherapy of postoperative osteosarcoma. The condensate forms through coordination‐driven liquid‐liquid phase separation between Hf 4+ ions and alendronate, enabling local retention within postoperative bone defects and sustained therapeutic release. Upon X‐ray irradiation, the Hf component amplifies radiation energy deposition and reactive oxygen species generation, thereby enhancing radiation‐induced DNA damage and immunogenic cell death. Meanwhile, the acidic tumor microenvironment triggers responsive release of CXB and ALN; CXB inhibits the COX‐2/PGE 2 immunosuppressive pathway, while ALN promotes macrophage repolarization toward the M1 phenotype, collectively remodeling the tumor immune microenvironment. This strategy enhances dendritic cell maturation, activates cytotoxic CD8 + T cells, and reduces regulatory T‐cell infiltration. In orthotopic osteosarcoma models, CXB@Hf‐ALN combined with RT suppresses tumor recurrence, preserves bone integrity, inhibits pulmonary metastasis, and prolongs survival with minimal systemic toxicity, offering a promising strategy to improve postsurgical RT outcomes in osteosarcoma.
- 21 July 2026
- Published by Elsevier in Biomaterials
- Vol. 336, 124477
Pathology-driven catalytic nanozyme–integrated adhesive hydrogel disrupts the hyperglycemia–ROS–hypoxia loop to accelerate vascularized fracture healing in diabetes
- 21 July 2026
- Published by Elsevier in Biomaterials
- Vol. 336, 124477
Pathology-driven catalytic nanozyme–integrated adhesive hydrogel disrupts the hyperglycemia–ROS–hypoxia loop to accelerate vascularized fracture healing in diabetes
- 20 May 2026
- Published by American Chemical Society (ACS) in ACS Applied Polymer Materials
- Vol. 8 (11) , 8269-8282
Self-Gelling Powder Driven by Electrostatic-Schiff Synergy Enables Blood-To-Gel Transformation for Rapid Hemostasis
- 20 May 2026
- Published by American Chemical Society (ACS) in ACS Applied Polymer Materials
- Vol. 8 (11) , 8269-8282
Self-Gelling Powder Driven by Electrostatic-Schiff Synergy Enables Blood-To-Gel Transformation for Rapid Hemostasis
- 13 February 2026
- Published by American Chemical Society (ACS) in ACS Applied Polymer Materials
- Vol. 8 (4) , 3158-3172
Recyclable and Degradable MXene-Based Conductive Hydrogels for Sustainable Multimodal Motion and Health Monitoring
- 13 February 2026
- Published by American Chemical Society (ACS) in ACS Applied Polymer Materials
- Vol. 8 (4) , 3158-3172
Recyclable and Degradable MXene-Based Conductive Hydrogels for Sustainable Multimodal Motion and Health Monitoring
- 13 January 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 391, 114617
Adaptive smart hydrogels driving precision bone healing in pathological contexts
- 13 January 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 391, 114617
Adaptive smart hydrogels driving precision bone healing in pathological contexts
- 10 September 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (37) , 33601-33619
Injectable Plant Phosphate Coordination Compound-Based Adhesive Hydrogel Accelerates Osteoporotic Fracture Healing by Restoring Osteoclast/Osteoblast Imbalance
Osteoporotic fractures are notoriously difficult to heal due to an imbalance between osteoblasts and osteoclasts. Current treatments often have limited efficacy or adverse side effects, necessitating safer and more effective solutions. Here, we developed an injectable plant-derived phosphate coordination compound-based adhesive hydrogel (MgPA-Gel) to restore bone homeostasis by integrating magnesium ions (Mg2+)-phytic acid (PA) nanoparticles with aminated gelatin (Gel-NH2) and aldehydated starch (AS). This hydrogel can firmly adhere to irregular bone surfaces at the fracture site and degrades in the acidic osteoporotic microenvironment, releasing PA and Mg2+ to modulate osteoclast and osteoblast activity. PA inhibits osteoclastogenesis by promoting monocyte secretion of cellular communication network factor 1 (CCN1), which disrupts Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-Receptor Activator of Nuclear Factor-κB (RANK) signaling, while Mg2+ enhances osteoblast differentiation from bone marrow stem cells. Hydrogel implantation synergistically augmented the fracture healing cascade in osteoporotic bone, achieving an 84.6% improvement in bending resistance compared to standalone intramedullary stabilization in ovariectomized (OVX) rats. This study highlights the potential of PA-based coordination compounds as a promising strategy for osteoporotic fracture treatment.
- 10 September 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (37) , 33601-33619
Injectable Plant Phosphate Coordination Compound-Based Adhesive Hydrogel Accelerates Osteoporotic Fracture Healing by Restoring Osteoclast/Osteoblast Imbalance
Osteoporotic fractures are notoriously difficult to heal due to an imbalance between osteoblasts and osteoclasts. Current treatments often have limited efficacy or adverse side effects, necessitating safer and more effective solutions. Here, we developed an injectable plant-derived phosphate coordination compound-based adhesive hydrogel (MgPA-Gel) to restore bone homeostasis by integrating magnesium ions (Mg2+)-phytic acid (PA) nanoparticles with aminated gelatin (Gel-NH2) and aldehydated starch (AS). This hydrogel can firmly adhere to irregular bone surfaces at the fracture site and degrades in the acidic osteoporotic microenvironment, releasing PA and Mg2+ to modulate osteoclast and osteoblast activity. PA inhibits osteoclastogenesis by promoting monocyte secretion of cellular communication network factor 1 (CCN1), which disrupts Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-Receptor Activator of Nuclear Factor-κB (RANK) signaling, while Mg2+ enhances osteoblast differentiation from bone marrow stem cells. Hydrogel implantation synergistically augmented the fracture healing cascade in osteoporotic bone, achieving an 84.6% improvement in bending resistance compared to standalone intramedullary stabilization in ovariectomized (OVX) rats. This study highlights the potential of PA-based coordination compounds as a promising strategy for osteoporotic fracture treatment.
- 16 July 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (28) , e2502888
Recent Advances in Dual‐Function Janus Membranes for Guided Periodontal and Bone Regeneration
Guided Tissue Regeneration (GTR) and Guided Bone Regeneration (GBR) are essential surgical techniques in periodontal therapy, employing barrier membranes to prevent soft tissue infiltration and create a conducive environment for bone regeneration. However, the regenerative performance of conventional barrier membranes remains limited due to poor interface management and insufficient biological functionality. Recent developments have introduced the concept of Janus membranes‐structures with asymmetric, dual‐function surfaces‐offering promising solutions to these challenges. While various reviews have addressed barrier membranes for periodontal and bone regeneration, comprehensive reviews specifically focusing on multifunctional Janus membranes are still limited. This review highlights recent advances in Janus membrane design for GTR and GBR applications. It first outlines key structural configurations, followed by an in‐depth analysis of fabrication techniques and functional strategies, including osteogenesis promotion, antibacterial activity, and immunomodulation. By summarizing current progress and challenges, this review offers valuable insights into next‐generation biomaterial development for periodontal regeneration. Looking forward, Janus membranes represent a compelling avenue for enhancing clinical outcomes in GTR and GBR procedures.
- 16 July 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (28) , e2502888
Recent Advances in Dual‐Function Janus Membranes for Guided Periodontal and Bone Regeneration
Guided Tissue Regeneration (GTR) and Guided Bone Regeneration (GBR) are essential surgical techniques in periodontal therapy, employing barrier membranes to prevent soft tissue infiltration and create a conducive environment for bone regeneration. However, the regenerative performance of conventional barrier membranes remains limited due to poor interface management and insufficient biological functionality. Recent developments have introduced the concept of Janus membranes‐structures with asymmetric, dual‐function surfaces‐offering promising solutions to these challenges. While various reviews have addressed barrier membranes for periodontal and bone regeneration, comprehensive reviews specifically focusing on multifunctional Janus membranes are still limited. This review highlights recent advances in Janus membrane design for GTR and GBR applications. It first outlines key structural configurations, followed by an in‐depth analysis of fabrication techniques and functional strategies, including osteogenesis promotion, antibacterial activity, and immunomodulation. By summarizing current progress and challenges, this review offers valuable insights into next‐generation biomaterial development for periodontal regeneration. Looking forward, Janus membranes represent a compelling avenue for enhancing clinical outcomes in GTR and GBR procedures.
- Top Cited PapersOpen Access
- 1 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-22
Injectable magnesium-bisphosphonate MOF-based bone adhesive prevents excessive fibrosis for osteoporotic fracture repair
Current treatments for osteoporotic fractures primarily target bone-resorbing osteoclasts, but they often fail to address fibrosis—a buildup of fibrous tissue that disrupts bone healing. This fibrosis is frequently triggered by bisphosphonates, which, while effective in reducing bone loss, also activate fibroblasts and impair callus formation. Here we show that an injectable hydrogel bone adhesive composed of magnesium-alendronate metal-organic frameworks (Mg-ALN MOF) embedded in a gelatin/dialdehyde starch network can simultaneously suppress bone resorption and reduce fibrosis. The Mg-ALN MOF adhesive binds firmly to irregular bone surfaces and degrades under acidic osteoporotic conditions, gradually releasing Mg2+ ions. These ions competitively bind to sclerostin (SOST), thereby interrupting the SOST/TGF-β signaling pathway that promotes fibroblast activation and abnormal collagen deposition. This dual-action mechanism significantly enhances fracture healing, resulting in a 27.8% improvement in flexural strength. Our findings suggest a promising therapeutic strategy that combines mechanical support with targeted regulation of both bone resorption and pathological fibrosis.
- 1 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-22
Top Cited PapersOpen AccessInjectable magnesium-bisphosphonate MOF-based bone adhesive prevents excessive fibrosis for osteoporotic fracture repair
Current treatments for osteoporotic fractures primarily target bone-resorbing osteoclasts, but they often fail to address fibrosis—a buildup of fibrous tissue that disrupts bone healing. This fibrosis is frequently triggered by bisphosphonates, which, while effective in reducing bone loss, also activate fibroblasts and impair callus formation. Here we show that an injectable hydrogel bone adhesive composed of magnesium-alendronate metal-organic frameworks (Mg-ALN MOF) embedded in a gelatin/dialdehyde starch network can simultaneously suppress bone resorption and reduce fibrosis. The Mg-ALN MOF adhesive binds firmly to irregular bone surfaces and degrades under acidic osteoporotic conditions, gradually releasing Mg2+ ions. These ions competitively bind to sclerostin (SOST), thereby interrupting the SOST/TGF-β signaling pathway that promotes fibroblast activation and abnormal collagen deposition. This dual-action mechanism significantly enhances fracture healing, resulting in a 27.8% improvement in flexural strength. Our findings suggest a promising therapeutic strategy that combines mechanical support with targeted regulation of both bone resorption and pathological fibrosis.